Effect of Neurotropin tablets for the treatment of Herpes zoster. Clinical evaluation of early treatment.
|
Accession number;03A0050349
|
| Title;Effect of Neurotropin tablets for the treatment of Herpes zoster. Clinical evaluation of early treatment. |
| Author;
TAKEMURA TSUKASA
(Shikiekimaehifuka)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.18;NO.11;PAGE.1255-1263(2002)
|
| Figure&Table&Reference;FIG.5, TBL.3, REF.11 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Antiviral agents and others in addition to NSAIDs and nerve blocking agents have been used for the treatment of herpes zoster. To avoid subsequent onset of postherpetic neuralgia, sufficient treatment of pain in the earlier period is considered important. In this study, Neurotropin tablet, the sole drug approved for the treatment of postherpetic neuralgia in Japan, was examined for efficacy in treating pain of the patients with herpes zoster. The drug was given twice daily (2 tablets each) in the morning and evening for 4 weeks or longer. Skin symptoms and pain were examined for symptom disappearance and judged by the Kaplan & Meier estimation method. Global improvement, safety, and usefulness were also judged. The number of subjects was 39, comprising 25 males (64.1%) and 14 females (35.9%). Those aged at 60 years old or more accounted for more than half (21 subjects, 53.8%), and average age was 59.1 years old. Severity of herpes zoster was Moderate in 31 subjects (79.5%), and Severe and Mild each in 4 (each 10.3%). Regarding details of the pain, "Pricking pain" predominated, accounting for 51.3% (20 subjects), "Dull pain" accounted for 33.3% (13), and "Burning pain" accounted for 7.7% (3), and it was revealed that a sign of neuropathic pain was already confirmed in the early stage. Aciclovir was concomitantly given to 35 subjects (89.7%) and NSAIDs were given to 7 subjects (17.9%).Pain disappeared in 25 subjects (64.1%), although some pain-associated symptoms persisted in 14 subjects (35.9%). In a follow-up study, 25 subjects answered the questionnaire, and persistent pain was complained of by only 1 subject (4.0%), showing good results of Neurotropin tablet in preventing transition from herpes zoster to postherpetic neuralgia. Global improvement rate was high, 94.9% (37/39), and no side effects were confirmed. It is concluded that Neurotropin tablet is an excellent and valuable drung for the pain control of herpes zoster in the acute stage. (author abst.) |
|
|
|
Related Articles;
|
|
